Of them, kallikrein 3 (hK3), or more commonly named as prostate-specific antigen (PSA), has gained prominence as the most valuable tumour marker and is currently used widely for the diagnosis, monitoring, and population screening for prostate cancer (Catalona et al, 1991; Mettlin et al, 1993). Here, HK3 is linked to prostate carcinoma.